Psychiatric Times World CME Congress

Treatment adherence remains a concern in psychiatry.

The FDA approved esketamine in 2019 for major depressive disorder.

Postpartum depression rates have increased since the COVID-19 pandemic.

Alcohol, stress, drug use, and not seeking help are all risk factors for chronic depression.

CBD has shown promise in treating anxiety and psychosis.

There remains a need for better treatments for bipolar disorder when it is identified early.

Mixed feature depression can be difficult to diagnose because the symptoms can be similar to other psychiatric disorders.

There remains a need for more research into the connection between grief and depression following a death.

Borderline personality disorder remains one of the most difficult to understand conditions in psychiatry.

Esketamine is seen as a major breakthrough in finding more treatments for depression.

Dr. Shear talked about the similarities and differences between depression and grief and the importance of recognizing both.